Business·Industry

SK Hanik to List U.S. ADRs Next Month… Raising 45 Trillion Won for Investments in Yongin and Cheongju Fab Facilities (Comprehensive)

45.5조 in New DR Shares Issued for ADR Listing on Nasdaq Funds Raised to Be Used for the Yongin Cluster, Cheongju Packaging, and Other Projects Expectations for Corporate Valuation Reassessment… Accelerated Investment in Semiconductor Equipment

[Edaily Kong Chi-Yu Reporter Kim So-yeon] SK hynix will list its depositary receipts (DRs) on the U.S. Nasdaq market next month. There are expectations that the company’s market value will rise as a result of an influx of global investors. Amid surging demand for artificial intelligence (AI) memory, SK hynix plans to use the funds raised to accelerate investments in production hubs, including the Yongin Semiconductor Cluster.
A view of SK hynix’s headquarters in Icheon, Gyeonggi Province. (Photo = Yonhap News)

SK hynix announced on the 24th that it will issue new American Depositary Receipts (ADRs) worth 45.4535 trillion won to list them on the Nasdaq Stock Market. The total number of shares to be issued is 17.79 million, the maximum allowable limit for new shares, and the price per share has been set at 2.555 million won, based on the closing price on the 23rd. The company aims to list on the Nasdaq market and begin trading on the 10th of next month.

DRs (Depositary Receipts) are substitute securities issued to facilitate the trading of a company’s shares in overseas markets. When issued in the United States, they are called ADRs. ADRs are securities that allow foreign companies to trade their shares with U.S. investors and are used to broaden the global investor base. Prior to the ADR listing, U.S. investors had to go through complex procedures—such as opening overseas accounts—to purchase SK hynix shares; however, after the listing, they will be able to trade SK hynix ADRs on the U.S. stock market in U.S. dollars, thereby increasing investment accessibility.

SK hynix plans to submit a securities registration statement to the Korea Exchange and a registration statement to the U.S. Securities and Exchange Commission (SEC). Once the securities registration statement becomes effective, SK hynix will begin the full public offering process, including a bookbuilding process for institutional investors and the determination of the offering price.

The 45조4535억원 raised by SK hynix through this ADR listing is scheduled to be invested entirely in capital expenditures. Specifically, the funds will be used for construction costs related to Phase 1 of the Yongin Semiconductor Cluster, as well as for the construction of the Cheongju Package & Test (P&T) 7 advanced packaging fab, along with equipment and ancillary expenses. SK hynix also plans to use the funds to acquire machinery, such as extreme ultraviolet (EUV) lithography equipment.

Previously, on March 25, SK hynix announced that it had submitted a registration statement to the SEC for its ADR listing and had begun the formal process of listing on the Nasdaq. SK Group Chairman Choi Tae-won officially confirmed the listing plans at NVIDIA’s annual developer conference, “GTC 2026,” held in San Jose, California, last March, stating, “This will allow us to reach not only Korean shareholders but also U.S. and global shareholders, enabling us to become a more global company.”

Industry observers believe that SK hynix’s corporate value could be reevaluated following this listing. Although SK hynix leads the AI memory market—including High Bandwidth Memory (HBM)—its corporate value is still considered lower than that of its U.S. competitor, Micron. There are also expectations that the inflow of funds from global investors will enable the company to accelerate investment in semiconductor facilities using the newly raised capital.

Economy

Corporation

IT·Science

Economy

A Semiconductor Fabless Company Founded by SK Hynix’s Youngest-Ever Executive [VC Cradle]

The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
2026-07-04 09:00:07

Corporation

Genosco, Tax Risk?… “Lecraza Is ‘Royalty Income’; Its Value Remains Unchanged”

Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
2026-07-04 08:31:02

IT·Science

Celltrion Pharm Inc. Builds a Plant, AriBio Secures Investment… K-Bio in ‘Expansion Mode’ [Weekly Bio Roundup]

As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
2026-07-04 09:01:02